LIXT exchanges preferred stock for common shares with Orbit Capital

Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) completed a share exchange with Orbit Capital Inc. on December 30, 2025, according to a company statement.

Under the agreement, Orbit Capital exchanged 2,700 shares of Lixte's Series C Preferred Stock for 700,000 shares of common stock and 200 ordinary shares of Liora Technologies Europe Ltd., representing 20% of the subsidiary's outstanding securities.

Following the transaction, all of Lixte's Series C Preferred Stock was cancelled. The company retained 800 ordinary shares of Liora Technologies Europe Ltd., its wholly-owned subsidiary incorporated under English and Welsh law.

Orbit Capital is incorporated in the Cayman Islands. Lixte Biotechnology Holdings is a Delaware corporation with common stock trading on NASDAQ.

You May Also Be Interested In

• Oppenheimer Initiates Palisade Bio Inc. (PALI) at Outperform
• American Critical Minerals plans $2M private placement for Utah drilling
• Cleveland-Cliffs (CLF) Misses Q2 EPS by 1c